HHS

The NIBIB is seeking applications from current grantees to develop life-saving technologies that can be ready for commercialization within one to two years. Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequently reissued equivalents.

• PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.

• PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional), which is intended to provide additional funds for NIH grantees for work that falls within the scope of their active grant.

NIDDK encourages the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:

• Collection of biosamples that could yield pathophysiologic insights into the impact of COVID-19 on HIV-associated CCCs within the mission of the NIDDK; especially those related to the gastrointestinal, liver, renal/urological, and metabolic/endocrine systems.
• Studies to gather data from health care systems and ongoing cohort studies to elucidate whether PWH with CCCs within the mission of the NIDDK have different COVID-19 outcomes.
• Studies that utilize nonhuman primate or ex vivo human models to characterize the effect of HIV-SARS-CoV-2 coinfection on gastrointestinal, liver, renal/urological, and metabolic/endocrine systems and processes.
• Studies to elucidate how HIV and SARS-CoV-2 coinfection impacts kidney or liver damage severity mediated by antiretroviral drugs.
• Pilot clinical studies designed to understand the natural history of COVID-19 related to either provoking or exacerbating HIV-associated CCCs within the mission of NIDDK, or to evaluate strategies for preventing or treating HIV-associated CCCs within the mission of NIDDK in the context of SARS-CoV-2 coinfection.

In order to rapidly improve our understanding and available control measures for COVID-19, NIDDK is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:

• Collection of biosamples that could inform the pathogenesis of COVID-19 associated kidney, gastrointestinal, or metabolic/endocrine diseases.
• Studies to gather data from health care systems and ongoing clinical trials to better understand whether patients with COVID-19 and diseases in the mission of NIDDK have different outcomes based on underlying disease factors or therapies for their condition.
• Studies to identify risk factors that could lead to modification of therapy in high risk individuals such as patients with acute kidney injury (AKI), organ transplantation, diabetes, inflammatory bowel disease, and other diseases within the mission of NIDDK that are treated with immunomodulators or biologic pathway inhibitors
• Studies to identify novel pathogenic pathways and potential translational targets for the development of kidney, gastrointestinal, endocrine and metabolic diseases associated with COVID-19 infection using relevant in vitro and in vivo studies of the kidney, gastrointestinal or endocrine/metabolism system.
• Pilot clinical studies designed to understand the natural history of COVID-19 related AKI, gastrointestinal or metabolic/endocrine diseases, or to evaluate interventions to prevent or treat COVID-19-induced AKI, digestive disorders, or metabolic/endocrine systems.

National Institute on Deafness and Other Communication Disorders (NIDCD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in relation to NIDCD’s scientific mission areas of hearing, balance, taste, smell, voice, speech and language.

The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa. Topics of specific interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infected persons in the context of cancer.

The NCI Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs encourage applications from small businesses with NCI-funded active NCI SBIR/STTR awards that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19) in cancer patients, cancer survivors, and in the general population. A compelling rationale should be presented and linked to an appropriate research plan to generate data in support of the new proposed use. Areas of interest include but not limited to:

• Adapting the use of cancer diagnostics and diagnostic technologies and platforms for diagnosing the virus, infection, and potential immunity against the virus rapidly at the point of care setting;
• Repurposing or expanding use of cancer vaccines, vaccine candidates, and other technologies for prevention of, and/or protection from SARS-CoV-2 infection;
• Repurposing or expanding the use of cancer therapeutics and therapeutic candidates for the treatment of COVID-19 and the management of severe symptoms.

Applicants are strongly encouraged to contact the NCI Program Director of the parent award to discuss potential applications and whether urgent competitive revision applications or administrative supplement requests are more appropriate for the proposed research.

NCCIH, NIA, and NIAAA are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

Now seeking abstract submissions for the following: 4.1-B Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus; 4.1-C: Diagnostic Tests for detection of COVID-19 disease; 4.3 COVID-19 Vaccine; 4.4 Advanced Manufacturing Technologies. The total Government share of funding, including options, of any project awarded under this EZ-BAA shall be less than $750,000.